menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Devonian Files New Patent For Thykamine As Antifibrotic Agent

    BUSINESSWIRE

    Devonian Reports Positive In Vivo Data For Thykamine In Fibrosis

    BUSINESSWIRE

    Devonian Reports Positive Results in MASH Liver Study

    BUSINESSWIRE

    Devonian Files Patent For Thykamine In Metabolic Steatohepatitis

    BUSINESSWIRE

    Devonian Reports Distribution Agreement Termination

    BUSINESSWIRE

    Devonian Reports Superior Anti-Inflammatory Potency of Thykamine

    BUSINESSWIRE

    Devonian Appoints Viktoria Krasteva as Chief Financial Officer

    BUSINESSWIRE

    Devonian Health Reports Q1 2025 Financial Results, Stock Options

    BUSINESSWIRE

    Devonian Reports Its Annual 2024 Financial Results

    BUSINESSWIRE

    Devonian Announces the Grant of Stock Options

    BUSINESSWIRE

    Devonian Health Group To Participate In Chicago Virtual Roadshow

    BUSINESSWIRE

    Devonian Health To Join Renmark`s LA Virtual Non-Deal Roadshow

    BUSINESSWIRE

    Devonian Health Group Reports Q3 2024 Results, Engages Investor Relations Firm

    BUSINESSWIRE

    Devonian Health Group to Join Renmark’s Boston Virtual Roadshow

    BUSINESSWIRE

    Devonian Appoints André Boulet Chairman & COO

    BUSINESSWIRE

    Devonian Reports Second Quarter 2024 Financial Results and Business Update

    BUSINESSWIRE

    Devonian Announces Closing of a Private Placement of Units

    BUSINESSWIRE

    Devonian Names Kathryn J. Gregory to Board of Directors and Grants Stock Options

    BUSINESSWIRE

    Altius, Launches Authorized Generic of Dexlansoprazole (Dexilant®) in Canada

    BUSINESSWIRE

    Devonian Announces a $2.16 Million Secured Term Loan

    BUSINESSWIRE

    Devonian Announces Results of Annual General and Special Shareholders` Meeting

    BUSINESSWIRE

    Devonian Bolsters Intellectual Property With Issuance of U.S. Patent

    BUSINESSWIRE

    Devonian Bolsters Leadership Team and Aligns Strategy

    BUSINESSWIRE

    Devonian Group Receives a Notice of Allowance for Issuance of a U.S. Patent

    BUSINESSWIRE

    Devonian Announces Closing of a Private Placement of $1.2 Million

    BUSINESSWIRE

    Devonian Announces Private Placement of up to $5 Million

    BUSINESSWIRE

    Devonian Health Group Announces Presentation of Thykamine™

    BUSINESSWIRE

    Devonian Announces Appointment of New Board Members and Grant of Stock Options

    BUSINESSWIRE

    Devonian Announces Approval of Amendments to its Stock Option Plan

    BUSINESSWIRE

    Devonian Health Group Announces voting results of the Annual General

    BUSINESSWIRE

    Devonian Announces Hybrid Shareholders’ Annual General and Special Meeting

    BUSINESSWIRE

    Devonian Health Announces its Participation at BIO CEO & Investor Conference

    BUSINESSWIRE

    Devonian Health Group Announces Executive Change and Grant of Stock Options

    BUSINESSWIRE

    Devonian to Present Thykamine PII Results at Dermatology Drug Development Summit

    BUSINESSWIRE

    Devonian Announces Publication of Thykamine Positive PII Trial Results

    BUSINESSWIRE

    Devonian Announces the Issuance of Units in Settlement of Interests

    BUSINESSWIRE

    Devonian Announces Executive Changes, Grant of Stock Options

    BUSINESSWIRE

    Devonian Health on Thykamine Positive PII Trial Results in Atopic Dermatitis

    BUSINESSWIRE

    Alpine Immune Sciences Reports Q4 and FY 2021 Financial Results

    BUSINESSWIRE

    Devonian Health Group Announces Trading on the OTCQB Market Under Symbol DVHGF

    BUSINESSWIRE

    Devonian to Issue Units in Settlement of Interests Owed to Debenture Holders

    BUSINESSWIRE

    Devonian Health Announces Voting Results of Annual General and Special Meeting

    BUSINESSWIRE

    Devonian Issues Units in Settlement of Interests Owed to Debenture Holder

    BUSINESSWIRE

    Devonian Announces Adoption of Shareholder Rights to a Private Placement

    BUSINESSWIRE

    Devonian Announces the Issuance of Subordinate Voting Shares

    BUSINESSWIRE

    Devonian Health Announces Appointment of Martin Moreau as Vice-President Finance

    BUSINESSWIRE

    Devonian Health Group Announces Closing of a Private Placement

    BUSINESSWIRE

    Devonian Announces the Issuance of Units in Settlement of Interests Owed

    BUSINESSWIRE

    DEVONIAN HEALTH GROUP ANNOUNCES DISTRIBUTION, SALE AND MARKETING AGREEMENT

    BUSINESSWIRE

    Devonian Group Announces Participation at Virtual BioPlus-Interphex Korea 2021

    BUSINESSWIRE

    Devonian Announces the Issuance of Units in Settlement of Interests Owed

    BUSINESSWIRE

    DEVONIAN HEALTH GROUP ANNOUNCES PARTICIPATION IN RENMARK VNDR SERIES

    PR NEWSWIRE

    Devonian Heath to Participate in Renmark’s Virtual Non-deal Roadshow Series

    PR NEWSWIRE

    Devonian Announces the Issuance of Units in Settlement of Interests Owed

    PR NEWSWIRE

    Devonian Health Group Announces Notice of Allowance for a US Patent

    BUSINESSWIRE

    Devonian Health Group Provides More Details on Previously Announced Positive

    BUSINESSWIRE

    Devonian Health Group Announces Positive Topline Results from Phase 2

    BUSINESSWIRE

    Devonian Health Group Announces Results from Ph 2 trial of Thykamine™

    BUSINESSWIRE

    Devonian Announces the Issuance of Units in Settlement of Interests Owed

    YAHOO

    Devonian Announces the Issuance of Units in Settlement of Interests Owed

    BUSINESSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.